Home›Allergy & Immunology› Pretreatment sTNFR1 and infection predict transplant-associated thrombotic microangiopathy in severe aplastic anemia
Pretreatment sTNFR1 and infection predict transplant-associated thrombotic microangiopathy in severe aplastic anemiaA simple blood test may flag a deadly transplant complication before it starts
Frontiers in MedicinePublished April 27, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider pretreatment sTNFR1 and infection status to assess early TA-TMA risk in severe aplastic anemia transplant candidates.
This prospective nested case–control study assessed patients with severe aplastic anemia undergoing allogeneic hematopoietic stem cell transplantation. The primary outcome was the prediction of early risk of transplant-associated thrombotic microangiopathy (TA-TMA), with secondary outcomes including mortality and death. Follow-up assessments occurred at days +7, +14, and +28.
Pretreatment sTNFR1 levels demonstrated a predictive ability with an area under the curve of 0.76 (95% CI, 0.60–0.91). Patients with elevated pretreatment sTNFR1 (≥1.93 ng/mL) faced a hazard ratio of 6.78 (95% CI, 2.26-20.3; p < 0.001) for TA-TMA and a hazard ratio of 21.44 (95% CI, 2.57-179; p = 0.005) for death. TA-TMA was associated with markedly higher mortality (59% vs. 1.3%).
Pre-transplant infections were linked to TA-TMA development, occurring in 11 of 19 (58%) infected patients versus 6 of 32 (19%) without infection. Infected patients also exhibited higher pretreatment sTNFR1 levels (1.93 vs. 1.64 ng/mL; p = 0.0034). The study suggests tumor necrosis factor-alpha–driven inflammation may precede clinical onset.
Safety data, adverse events, and discontinuations were not reported. As an observational study, results suggest associations rather than causation. Practice relevance indicates sTNFR1 may be a useful early-warning biomarker, and infection control before transplantation may reduce risk.
This doesn’t mean this treatment is available yet.
Experts note that these findings point to a clear biological story. Tumor necrosis factor-alpha, a key inflammatory signal, appears to drive early risk. Measuring sTNFR1 may give doctors a window into that process before clinical signs appear. That could allow earlier interventions, such as closer monitoring or infection control.
For patients and families, this could mean more time to prepare and more personalized care. If a high sTNFR1 level is found before transplant, doctors might take extra steps to reduce infection risk or adjust supportive care. It could also help guide conversations about risk and expectations. But it’s important to remember that this is not a routine test yet.
The study has limits. It focused on a specific group—patients with severe aplastic anemia—and the sample size was modest. The findings need to be confirmed in larger, more diverse groups. The test itself is promising, but it’s not ready for widespread use without further validation.
What happens next? Researchers will likely test sTNFR1 in larger studies and in other transplant settings. If the results hold, this marker could become part of routine pre-transplant screening. That would be a meaningful step toward preventing a deadly complication and improving outcomes for patients who need a transplant the most.
BackgroundTransplant-associated thrombotic microangiopathy (TA-TMA) is a severe and potentially fatal complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early identification of patients at risk is essential for timely intervention and improved outcomes. This study aimed to identify biomarkers capable of predicting the early risk of TA-TMA in patients with severe aplastic anemia (SAA) undergoing allo-HSCT.MethodsIn a prospective nested case–control study of patients with SAA undergoing allo-HSCT, blood samples were collected before pretreatment, before infusion, and on days +7, +14, and +28. TA-TMA cases were matched 1:2 to controls. Biomarkers were compared, and predictive performance was assessed using Receiver operating characteristic analysis and Cox models.ResultsTA-TMA was associated with markedly higher mortality (59% vs. 1.3%). Soluble tumor necrosis factor receptor 1 (sTNFR1) consistently showed the strongest predictive ability, including before pretreatment (area under the curve 0.76; 95% CI, 0.60–0.91). A cutoff of 1.93 ng/mL yielded 0.88 specificity and 0.69 sensitivity. Elevated pretreatment sTNFR1 (≥1.93 ng/mL) predicted TA-TMA (hazard ratio, 6.78; 95% CI, 2.26-20.3; p < 0.001) and death (21.44; 95% CI, 2.57-179; p = 0.005). 19 had pre-transplant infections, of whom 11 (58%) developed TA-TMA versus 6 of 32 (19%) without infection. Infected patients also showed higher pretreatment sTNFR1 levels (1.93 vs. 1.64 ng/ml, p = 0.0034).ConclusionsPretreatment sTNFR1 is a strong early predictor of TA-TMA and mortality in patients with SAA undergoing allo-HSCT, suggesting Tumor Necrosis Factor-alpha–driven inflammation precedes clinical onset. sTNFR1 may be a useful early-warning biomarker, and infection control before transplantation may reduce risk.
